Breast Implant Information Updates

A Statement on Breast Implant Safety

Breast implants are amongst the most used and most highly studied implantable medical devices in the world. Important lessons were learned from historical incidents which have resulted in improvements in the international regulatory system and the widespread introduction of national breast implant registries.

The establishment of effective national breast device registries combined with international collaboration has the ability to significantly improve health outcomes for patients with implantable breast devices globally.

The published literature indicates that breast implants are thought to be safe in general but can have rare, serious side effects. These side effects have been studied extensively, especially in the field of auto-immune diseases such as Sjogren’s syndrome and rheumatoid arthritis and a rare form of lymphatic cancer, BIA-ALCL.

View Full Statement

Assess implants for no out-of-pocket expense consultation - 30 August 2017

Update on Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA‐ALCL)

Women who are concerned about their breast implants following reports of a study linking infection caused by implants to a rare cancer, anaplastic large cell lymphoma (ALCL), should discuss their concerns with their doctor.

ASPS is developing a national register of member surgeons who are willing to see concerned women with symptoms and assess their implants for no out-of-pocket expense consultation. The patients first option should be to see the surgeon who put the implants in but if they can’t or don’t want to, then members on the register will see the patient for an assessment with a referral from their GP.

This initial consultation is an opportunity to discuss concerns. If the patient chooses to undertake further investigation or commit to a procedure, subsequent costs may be incurred.

The register can be accessed here.

FAQ’s – 28 August 2017

FAQS on breast implant associated with anaplastic large cell lymphoma (BIA-ALCL)

The Therapeutic Goods Administration (TGA) has recently provided updated information regarding breast implant associated-anaplastic large cell lymphoma.

The TGA has been posting updated information about this condition since 2011 and this updated alert was been generated following a recent expert advisory panel in view of additional generated from research performed by a joint BIA-ALCL task force with representatives from the Australian Society of Plastic Surgeons, Australasian Society of Aesthetic Plastic Surgeons, New Zealand Association of Plastic Surgeons the Australian Breast Device Registry and the Peter MacCallum Cancer Centre

Information Sheet – 28th August 2017

Key points and facts associated with BIA-ALCL

Breast implant associated-Anaplastic Large Cell Lymphoma (BIA-ALCL)

Read More

Specialist Plastic Surgeons’ statement on breast implant associated Anaplastic large cell Lymphoma

Read More